Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alprostadil topical - Seelos Therapeutics

Drug Profile

Alprostadil topical - Seelos Therapeutics

Alternative Names: Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Topical ED treatment - Seelos Therapeutics; Virirec; Vitaros; Vytaros; WC-3036

Latest Information Update: 29 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NexMed
  • Developer Apricus Biosciences; Ferring Pharmaceuticals; Laboratoires Majorelle; Recordati; Seelos Therapeutics
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Erectile dysfunction
  • Phase II Raynaud's disease
  • Suspended Female sexual dysfunction
  • No development reported Premature ejaculation; Wounds

Most Recent Events

  • 25 Jan 2019 Seelos Therapeutics merged with Apricus Biosciences to form Seelos Therapeutics
  • 16 Apr 2018 Alpostadil topical is available for licensing in USA
  • 26 Mar 2018 End of review meeting for alprostadil topical with US FDA scheduled on 12/04/2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top